The Kidney Cancer Research Alliance (KCCure) announced today the formation of a national kidney cancer Patient Advisory Board; a non-voting body made up of patients, caregivers and leaders in the cancer community. The board will be led by patient advocates Michael B. Lawing and Debra Gottsleben.
WASHINGTON - Kidney Cancer Research Alliance (KCCure) President Dena Battle has been elected to the National Cancer Institute’s Renal Task Force to serve as one of two patient advocates on the panel.
New data from the pivotal phase 3 Checkmate 214 trial combining ipilumimab and nivolumab presented at the European Society of Medical Oncology (ESMO) conference in Madrid showed superiority for the combination over Sunitinib (Sutent). This data will likely mean that the IO combination will move to approval for first line stage 4 RCC therapy.
The Kidney Cancer Research Alliance (KCCure) announced today that their first research grant of $100,000 has been awarded to Dr. Wayne Marasco, at Dana Farber Cancer Center for his proposal: CAR T-Cell Factories that change the Tumor Microenvironment to Achieve RCC Cures.
For our part, in honor of World Kidney Cancer Day – we are proud to announce that our first grant of $100,000 is being awarded to Dr. Wayne Marasco at Dana Farber Cancer Center for his continuing efforts to translate CAR T-Cell Therapy into a new treatment for kidney cancer.
As members of the International Kidney Cancer Coalition (IKCC), KCCure is a proud partner and participant of the first-ever World Kidney Cancer Q&A Day. On June 22, 2017, patients, caregivers, health care professionals and local organizations from around the world will join together to raise awareness about kidney cancer.
I’ll be honest, there’s something about the word “awareness” that I’ve never really liked – I think it’s because I wish we didn’t have to be aware of kidney cancer. And I suppose it makes sense, because our goal at KCCure is to raise money for research to eliminate kidney cancer – to end the need for an awareness month. But for now, there are too many reminders that it still exists. Spending the day yesterday with a patient, I was reminded how little we know about rare subtypes like Translocation Xp112. At the ASCO-GU conference in Florida last month, we saw papers presented on the need for more knowledge about Renal Medullary Carcinoma, a rare and aggressive variant of kidney cancer. We heard from Dr. Marston Linehan about how far we’ve come in finding genetic ...
After 11 years fighting kidney cancer, the gifts of life are everywhere, even in clinical trials.
As with cancer research, when it comes to fundraising, small advances add up to big change.
For kidney cancer, more research is needed for genomic analysis to inform personalized treatments.